Arthritis Treatment Alternatives in Middle Tennessee: Beyond Medication and Surgery

Arthritis affects more than 58 million adults in the United States, and in Middle Tennessee the numbers reflect that national pattern. Osteoarthritis is the most common form, and it affects nearly every joint in the body as cartilage breaks down over time under the combined pressures of age, use, prior injury, and genetic predisposition. For the majority of patients, the path through the healthcare system begins with a primary care diagnosis, proceeds through a conventional treatment sequence, and eventually arrives at a fork: continue managing symptoms that are no longer adequately controlled, or pursue more advanced options.

This article is written for patients who have arrived at that fork and want to understand what regenerative medicine alternatives exist in Middle Tennessee, what the science says about them, and how to evaluate candidacy honestly.

The Arthritis Treatment Default Path

How Most Patients Are Managed Initially

The standard initial management of osteoarthritis in Middle Tennessee follows a nationally consistent pattern. A primary care physician or orthopedist makes the clinical diagnosis, typically confirmed by X-ray showing joint space narrowing and osteophyte formation. From there, a conventional first-line protocol is initiated.

Non-steroidal anti-inflammatory drugs (NSAIDs) are almost universally the first pharmacological tool. Ibuprofen, naproxen, meloxicam, and celecoxib are among the most commonly prescribed. They manage the inflammatory component of arthritis pain and reduce swelling, and for mild to moderate early osteoarthritis, they provide meaningful short-term relief.

Activity modification is usually recommended alongside medication. High-impact activities that load the affected joint are typically restricted. Weight loss counseling is standard for patients with knee or hip OA, given the well-established biomechanical relationship between body weight and joint loading forces.

Physical therapy referral is typically part of the initial management plan. A physical therapist working with an arthritic joint focuses on strengthening the surrounding musculature (particularly quadriceps and hip abductors for knee OA), improving joint mobility, and optimizing movement patterns to reduce destructive loading forces.

Viscosupplementation with hyaluronic acid injections is offered by some orthopedic practices, particularly for knee OA. These injections aim to restore synovial fluid viscosity. Evidence for their efficacy is mixed in the literature, with some systematic reviews questioning their superiority over saline placebo. The Bone and Joint Institute of Tennessee in Franklin/Brentwood, led by Dr. Cory Calendine, represents a local practice that explores comprehensive nonsurgical options including advanced injection therapies before considering surgical intervention.

Where NSAIDs and Cortisone Reach Their Structural Limits

NSAIDs are symptom managers. They reduce pain and inflammation effectively but do not alter the underlying disease process. Cartilage continues to break down regardless of how well NSAID medications control pain. Long-term NSAID use carries documented risks including GI bleeding and ulceration, reduced kidney function with chronic use, and cardiovascular effects that require monitoring in higher-risk patients. For patients who depend on NSAIDs for daily function, the long-term risk profile becomes increasingly relevant over years of use.

Cortisone (corticosteroid) injections are among the most commonly administered procedures in arthritis management. They provide rapid anti-inflammatory relief that many patients find valuable for acute flares. However, the research on repeated cortisone injections is worth understanding. Published studies have raised concerns about cartilage volume loss with repeated intra-articular corticosteroid injections, with one frequently cited trial showing accelerated radiographic progression in knee OA patients receiving quarterly cortisone compared to hyaluronic acid. The frequency and total number of cortisone injections that any individual joint should receive is a point of ongoing clinical discussion.

The practical reality is that many Middle Tennessee patients eventually reach a treatment plateau. Their NSAIDs no longer provide adequate daily relief, their cortisone injections produce shorter and shorter periods of benefit, and the orthopedic surgeon has indicated that they are not yet at the severity level that would make replacement surgery appropriate or advisable. This is the population most actively looking for alternatives.

What Regenerative Medicine Offers Arthritis Patients

PRP for Inflammatory Arthritis Symptoms

Platelet-rich plasma (PRP) therapy for osteoarthritis involves drawing a sample of the patient’s own blood, processing it to concentrate the platelets and their associated growth factors, and injecting that concentrated product into the affected joint under ultrasound guidance for precision delivery.

The mechanism is not fully understood, but research suggests that the growth factors present in PRP, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), and insulin-like growth factor (IGF), may reduce joint inflammation and support the biological environment needed for tissue maintenance.

The evidence base for PRP in knee OA is among the strongest in regenerative medicine. Multiple randomized controlled trials have compared PRP to hyaluronic acid injections and to saline placebo. A number of these studies, and several systematic reviews aggregating them, show that PRP produces greater improvements in pain and function at 6 and 12 months compared to hyaluronic acid, with a favorable comparison to placebo as well. The evidence for hip, shoulder, and ankle OA is less developed but represents an active area of clinical research.

PRP is generally the first regenerative option considered for arthritis patients. The procedure is minimally invasive, the risk profile is low given that it uses the patient’s own blood, and the evidence supporting its use in early to moderate osteoarthritis is the most accessible of any regenerative option. In Middle Tennessee, clinics including MaxWell Clinic in Nashville and physician-led regenerative practices in Franklin offer PRP for arthritic joints as part of their regenerative services.

A2M for Cartilage Preservation: The Disease-Modification Argument

Alpha-2-macroglobulin (A2M) is a naturally occurring protein found in blood plasma that functions as a broad-spectrum protease inhibitor. Its relevance to osteoarthritis lies in the biology of cartilage destruction.

Osteoarthritis is not simply a matter of mechanical wear. The cartilage breakdown process is driven significantly by enzymatic activity. Matrix metalloproteinases (MMPs) and a class of enzymes called aggrecanases (particularly ADAMTS-4 and ADAMTS-5) are responsible for degrading the collagen and proteoglycan structure of articular cartilage. Research suggests that these enzymes are upregulated in arthritic joints and that their activity drives progressive cartilage loss.

A2M inhibits these enzymes. It captures and neutralizes the proteases responsible for cartilage breakdown, potentially interrupting the disease mechanism rather than simply managing its symptomatic output. This is the basis for the claim that A2M may be disease-modifying in a way that anti-inflammatory treatments are not.

The distinction between disease-modifying treatment and symptomatic treatment is clinically important. A symptomatic treatment reduces pain without changing the underlying disease course. A disease-modifying treatment alters the biological process driving damage. If A2M’s protease-inhibiting activity translates into measurable cartilage preservation over time, it would represent a meaningful advance in arthritis management. The clinical evidence for this is still developing, and long-term trials examining cartilage volume changes are ongoing, but the mechanistic rationale is well-grounded in the known biology of osteoarthritis.

For patients in Middle Tennessee who are in early to moderate stages of OA and are motivated to slow progression rather than simply manage symptoms, A2M represents a biologically rational option to discuss with a regenerative physician.

Stem Cell Therapy for Joint Tissue Support

Autologous mesenchymal stem cell (MSC) therapy represents the most biologically comprehensive option in the regenerative medicine toolkit for osteoarthritis. MSCs are harvested from the patient’s own bone marrow or adipose (fat) tissue, processed in a laboratory, and then injected into the affected joint.

What distinguishes MSC therapy from PRP is not simply the cell type but the biological mechanism. While PRP delivers concentrated growth factors, MSCs are living cells with paracrine signaling capabilities. They release growth factors, cytokines, and signaling molecules that communicate with the surrounding joint environment. Research suggests that MSCs may promote an anti-inflammatory joint milieu, support cartilage cell (chondrocyte) function, and potentially contribute to cartilage matrix formation in some cases.

The quality of MSC therapy is significantly affected by how the cells are collected, processed, and delivered. Many regenerative clinics in Middle Tennessee and nationally use external laboratories for cell processing, which introduces variability in turnaround time, cell viability, and quality documentation. A physician-led practice in Franklin processes autologous stem cells in an on-site laboratory under direct physician supervision, allowing for documented cell count and viability at the time of injection. This level of quality control represents a meaningful differentiator in an environment where laboratory practices vary widely.

What Regenerative Therapy Can and Cannot Reverse

Early and Moderate Arthritis: Where the Evidence Points

The Kellgren-Lawrence (KL) grading system is the standard radiographic classification for osteoarthritis severity:

Grade 1: Possible joint space narrowing, small osteophytes
Grade 2: Definite osteophytes, possible joint space narrowing
Grade 3: Multiple osteophytes, definite joint space narrowing, some sclerosis
Grade 4: Large osteophytes, marked joint space narrowing, severe sclerosis, possible bony deformity

Clinical evidence for regenerative therapies is most developed for KL grades 1 through 3. At these stages, cartilage is damaged but still present, and the joint environment contains the biological infrastructure that regenerative signals can interact with. Published outcomes data at 6 and 12 months post-treatment consistently shows improvements in validated pain and function scores in a meaningful proportion of patients with early to moderate OA.

The framing of “clinically meaningful improvement” in published research is important to understand. Most studies define clinical success as a reduction in pain score of 50% or more, or an improvement in functional scores (such as KOOS for knee, or HOOS for hip) that exceeds the minimum clinically important difference for those instruments. Many patients in these studies meet those thresholds. Not all patients do, and the response varies with age, body weight, disease severity, activity level, and other factors.

Advanced Joint Destruction: Honest Expectations

KL grade 4 osteoarthritis, the stage colloquially described as “bone-on-bone,” presents a fundamentally different biological situation. The articular cartilage that regenerative agents would interact with has been largely or entirely lost. The joint surfaces are in direct bony contact.

Regenerative therapy cannot restore cartilage that no longer exists. The biological mechanisms that PRP and stem cell therapy engage depend on some residual cartilage tissue and a joint environment that can respond to repair signals. When that environment is absent, the rationale for biological repair intervention is significantly weakened.

Patients with grade 4 OA who are hoping to avoid surgery entirely may still benefit from symptom management approaches, and some regenerative physicians will discuss anti-inflammatory options in this context. However, a candid and ethical candidacy assessment at any responsible regenerative clinic will include a clear explanation of what the imaging shows and what can and cannot be expected from biological intervention at that stage.

Some grade 4 patients who are not surgical candidates due to age, comorbidities, or personal preference may find partial symptomatic benefit from some regenerative approaches. This is a clinical judgment that should be made on an individual basis with full transparency about expectations.

How to Know Which Category You Are In

Patients cannot reliably self-assess their OA severity based on symptoms alone. Pain intensity does not reliably correlate with imaging severity. Some patients with grade 4 disease have less pain than others with grade 2. The only way to determine OA severity objectively is through imaging.

Standard X-ray provides the KL grade and is sufficient for initial severity classification. MRI provides cartilage detail beyond what X-ray captures, including the thickness and composition of remaining cartilage, the presence of bone marrow lesions, and the state of the menisci in the knee. For patients considering regenerative therapy, MRI adds information that X-ray cannot provide and is often recommended as part of a thorough candidacy assessment.

A physician-led candidacy discussion that includes imaging review is the appropriate mechanism for determining where you fall in the OA severity spectrum and what biological intervention can reasonably offer at that stage.

How Middle Tennessee Clinics Assess Arthritis Severity

Imaging Grading and What the Numbers Mean

The KL grading system is the most commonly used radiographic tool for OA severity. Understanding what each grade means structurally helps patients engage more productively in their candidacy conversations.

Grade 1 shows possible narrowing of the joint space and questionable osteophyte formation. The joint is showing early degenerative changes that may not yet be producing significant symptoms but represent a window in which preventive intervention has its strongest theoretical rationale.

Grade 2 confirms the presence of osteophytes (bone spurs at joint margins) and shows possible joint space narrowing. This is typically the point at which OA becomes a formal diagnosis and when many patients begin exploring additional treatment options beyond primary care management.

Grade 3 shows multiple osteophytes, definite joint space narrowing, some subchondral sclerosis (bone hardening beneath the cartilage), and possible bony deformity. Patients at this stage are typically experiencing significant functional limitations and have often exhausted conservative management.

Grade 4 shows large osteophytes, marked joint space narrowing, severe sclerosis, and often bony deformity. This is the stage where surgical consultation is typically initiated.

For patients considering regenerative medicine, knowing their KL grade before a consultation allows the physician to discuss candidacy based on objective findings rather than symptoms alone.

For more detailed cartilage assessment, MRI-based scoring systems such as MOAKS (MRI Osteoarthritis Knee Score) or WORMS (Whole-Organ Magnetic Resonance Imaging Score) provide a granular assessment of cartilage morphology, signal changes, and bone marrow lesions that can help guide intervention decisions beyond what KL grading provides.

How Outcomes Are Tracked Over 6 and 12 Months

Responsible regenerative medicine practices track patient outcomes using validated clinical measurement tools rather than relying on subjective patient reports alone. For Middle Tennessee patients undergoing regenerative treatment for arthritis, the assessment tools most commonly used include:

The KOOS (Knee injury and Osteoarthritis Outcome Score) for knee conditions, covering subscales for pain, symptoms, activities of daily living, sport and recreation function, and knee-related quality of life.

The HOOS (Hip disability and Osteoarthritis Outcome Score) for hip conditions, with an analogous subscale structure.

The ASES (American Shoulder and Elbow Surgeons) score for shoulder conditions.

Pain intensity is typically measured with a Visual Analog Scale (VAS) or Numeric Rating Scale (NRS) at each follow-up visit.

Functional assessments such as the Timed Up and Go test, Chair Stand Test, and 6-Minute Walk Test provide objective functional data that complements patient-reported outcomes.

Imaging is typically repeated at 6 to 12 months post-treatment in cases where cartilage changes are a primary concern, using MRI for cartilage-specific assessment when baseline MRI established the starting point.

When patients show incomplete response to a first course of regenerative treatment, a physician at a well-structured clinic will review the outcome data, reassess imaging if appropriate, and discuss whether a second treatment cycle, a different intervention, or a different care pathway is most appropriate for that individual’s situation.

Sources

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.